Research on the Relationship Between Cognitive Function Changes and Cerebrovascular Health in Patients With Coronary Heart Disease

Evaluation and Prognosis of Cerebrovascular and Neurological Health Status in Patients With Coronary Heart Disease After Treatment

The purpose of this study is to elucidate the imaging mechanisms of cognitive function changes in patients with coronary heart disease before and after surgery or conservative treatment, and to evaluate and predict the postoperative neurological function recovery and cerebrovascular health level of patients by combining serum markers and patient cardiovascular health evaluation indicators.

The focus of this study is to elucidate the impact of coronary heart disease on the morphology and cognitive changes of cerebral blood vessels in patients. Record imaging data, neuropsychological cognitive scales, serum markers, adverse cardiac events, and patient evaluation indicators before and after clinical treatment and follow-up period, and explore relevant factors affecting changes in cerebrovascular morphology and cognitive function.

Inclusion Criteria:

• Confirmed coronary heart disease or risk of coronary heart disease through clinical testing
• Conscious and capable of completing neuropsychological scales

Exclusion Criteria:

• Patients with other serious heart diseases (such as aortic aneurysm)
• People with uncontrolled hypertension or diabetes
• There are contraindications to MRI examination (there are metal implants in the body, such as cardiac pacemakers, metal dentures, artificial joints, non paramagnetism stents, etc.; there is claustrophobia)
• Have a history of severe stroke, epilepsy, traumatic brain injury, and transient ischemic events
• Existence of neurological and mental disorders (schizophrenia, depression, etc.), post-traumatic stress disorder, obsessive-compulsive disorder, multiple sclerosis, amyotrophic lateral sclerosis, etc
• Have a history of alcohol or drug abuse
• Those with significant organ dysfunction such as lung, liver, and kidney;
• Patients with tumor, infectious diseases, blood system disease and immune system disease;
• Currently participating in other clinical studies at the same time.